Trial Profile
A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Ulcerative Colitis (UC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Eldelumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 10 Dec 2022 This trial has been discontinued in Germany according to European Clinical Trials Database record.
- 22 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Oct 2014 Planned End Date changed from 1 Jan 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov.